# Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations

Source: https://onco.cc/trials/nct07628504/  
OnCo record `nct07628504` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of sacituzumab tirumotecan and capecitabine in triple-negative breast cancer, run by Fudan University, not yet recruiting.

## Summary

Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations. ClinicalTrials.gov record last updated 2026-06-05: not yet recruiting. Enrollment is planned at 420 participants. Primary completion is estimated at 2030-03-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab Tirumotecan (sac-TMT), Capecitabine. Registered primary measures: Disease-Free Survival (DFS).

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-10-06
- Also known as: STARTER
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07628504
- Phase: 3
- Setting: Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
- Sponsor: Fudan University
- Enrolled: 420

## Notes

- ClinicalTrials.gov record last updated 2026-06-05: not yet recruiting. Enrollment is planned at 420 participants. Primary completion is estimated at 2030-03-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT07628504: https://clinicaltrials.gov/study/NCT07628504

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07628504.json